Why the study?
Diabetic cardiomyopathy is a major cause of death in diabetes, but the effect of sacubitril/valsartan on myocardial fibrosis in DCM remains unclear.
Does sacubitril/valsartan reduce myocardial fibrosis in diabetic cardiomyopathy rats?
Does sacubitril/valsartan reduce myocardial fibrosis in diabetic cardiomyopathy rats?
Sacubitril/valsartan demonstrates potential to alleviate myocardial fibrosis in a rat model of diabetic cardiomyopathy.
Should not yet change practice for diabetic cardiomyopathy; leaves open whether these anti-fibrotic mechanisms translate from.
Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats Diabetic cardiomyopathy (DCM) is one of the most important causes of death in patients with diabetes mellitus. 1Myocardial inflammation is the basic pathophysiological process in the occurrence and development of DCM.Sacubitril/valsartan (Sac/Val) is the first angiotensin receptoreneprilysin inhibitor (ARNI) in the world. 2 It can reduce the degradation and increase the concentration of natriuretic peptides, and inhibit the release of renin and aldosterone. 3,4The initial medication strategy with Sac/Val may reduce the short-term risk of adverse events and simplify the treatment process in heart failure patients. 5However, the effect of Sac/ Val on myocardial fibrosis in DCM remains unclear.Therefore, in this study, we sought to assess the effect of Sac/Val on myocardial fibrosis.
No takes yet. Share an insight, caveat, or question.
Ai et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: